Arcadia Biosciences Inc (RKDA)

Form 8-K - Current report

Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

DALLAS, June 12, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer...

Arcadia Biosciences (RKDA) Announces $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules

DALLAS, June 11, 2026 (GLOBE NEWSWIRE) -- Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer...

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Arcadia Biosciences (RKDA) Announces First Quarter 2026 Financial Results and Business Highlights

 -- Zola® volumes increase 18% year-over-year -- -- SG&A at lowest level in Arcadia’s history -- DALLAS...

Form 8-K - Current report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Arcadia Biosciences (RKDA) Announces Fourth-Quarter and Full-Year 2025 Financial Results and Business Highlights

-- Zola® revenues increase 17% year-over-year -- -- Arcadia and Roosevelt Resources terminate proposed...

Form EFFECT - Notice of Effectiveness

Form 8-K - Current report

Form RW - Registration Withdrawal Request

Arcadia Biosciences (RKDA) Announces Exercise of Preferred Investment Options for $2.1 Million Gross Proceeds

DALLAS, Jan. 12, 2026 (GLOBE NEWSWIRE) --  Arcadia Biosciences, Inc.® (Nasdaq: RKDA), a producer and marketer...